The Leerink Swann Weighs in on Paratek Pharmaceuticals Inc.’s Q3 2016 Earnings (PRTK)

The Leerink Swann Weighs in on Paratek Pharmaceuticals Inc.’s Q3 2016 Earnings (PRTK)

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) – Equities researchers at Leerink Swann issued their Q3 2016 earnings per share (EPS) estimates for Paratek Pharmaceuticals in a note issued to investors on Thursday. Leerink Swann analyst P. Matteis forecasts that the brokerage will earn ($1.48) per share for the quarter. Leerink Swann has a “Outperform” rating and a $23.00 price target on the stock. Leerink Swann also issued estimates for Paratek Pharmaceuticals’ Q4 2016 earnings at ($1.25) EPS, FY2016 earnings at ($6.06) EPS and FY2017 earnings at ($4.89) EPS.

A number of other analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 6th. Guggenheim restated a “buy” rating on shares of Paratek Pharmaceuticals in a report on Tuesday, August 16th. Finally, HC Wainwright restated a “buy” rating on shares of Paratek Pharmaceuticals in a report on Tuesday, August 16th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $34.38.

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) opened at 11.10 on Monday. The firm’s market capitalization is $251.16 million. Paratek Pharmaceuticals has a 12-month low of $10.75 and a 12-month high of $22.00. The stock has a 50 day moving average of $13.05 and a 200-day moving average of $13.75.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.66) by $0.03.

Institutional investors have recently modified their holdings of the company. Stoneridge Investment Partners LLC purchased a new position in shares of Paratek Pharmaceuticals during the second quarter worth about $329,000. Turner Investments L.P. bought a new position in shares of Paratek Pharmaceuticals during the second quarter valued at $883,000. Candriam Luxembourg S.C.A. bought a new position in shares of Paratek Pharmaceuticals during the second quarter valued at $556,000. BVF Inc. IL bought a new position in shares of Paratek Pharmaceuticals during the second quarter valued at $7,998,000. Finally, Birchview Capital LP bought a new position in shares of Paratek Pharmaceuticals during the second quarter valued at $155,000. Institutional investors own 77.22% of the company’s stock.

Paratek Pharmaceuticals Company Profile

Related posts

Leave a Comment